NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...

ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

Watch the video to see the initiatives Neurizon is taking. This video was developed in collaboration with Neurizon ...

Telix Pharmaceuticals (ASX:TLX) has won marketing approval for its prostate cancer imaging agent in Brazil, marking the ...

Neurizon Therapeutics has submitted a formal request to the US Food and Drug Administration (FDA) for clarification on two ...

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 ...

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...